Cooley advised Accolade on its $253.6 million initial public offering of 11,526,134 shares of common stock, including full exercise of the underwriters’ option to purchase additional shares. Accolade, whose securities now trade on the Nasdaq Global Select Market under the symbol “ACCD,” is a healthcare technology company that provides personalized healthcare services and benefits solutions to employees using a range of technologies. Partners John Robertson and Alan Hambelton led the Cooley team.
